BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19^high B lymphocytes.

ABSTRACT:

Background

The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor. The purpose of this study was to investigate the therapeutic potential of chemotherapy combined with inhibition of B and T lymphocyte attenuator (BTLA) for clinical use to treat EOC.

Methods

Initially, we evaluated the potential application of chemotherapy combined with anti-BTLA antibody in an animal model. We then analyzed the distribution and regulation of BTLA expression on immunocytes in vitro. Finally, we examined the correlation between BTLA expression levels in cancerous tissues and prognosis in 254 EOC cases.

Results

The combination of chemotherapy and anti-BTLA antibody for inhibiting B

SUBMITTER: Chen YL 

PROVIDER: S-EPMC6868712 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature